Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (278)	1/5/2005 7:17:50 PM
From: caly	Read Replies (1) \| Respond to of 377

See bold for competing products... Reducing inflammation as an emerging target for cardiovascular disease A number of studies have shown that inflammation of blood vessels is one of the major factors that increases the incidence of heart diseases, including atherosclerosis (clogging of the arteries), stroke and myocardial infarction or heart attack. Studies have associated obesity and other components of metabolic syndrome, cardiovascular risk factors, with low-grade inflammation. Furthermore, some findings suggest that drugs commonly prescribed to lower cholesterol also reduce this inflammation, suggesting an additional beneficial effect of the statins. This report focuses on various aspects of blood vessel inflammation; from definition to its causes. Further, the report analyses how inflammation could be a threat to the heart and life and various therapies to for reducing inflammation including losing weight, exercising and use of statins and ACE inhibitors. The report, step-by-step, covers information key to the emmerging field of vascular inflammation and concludes with a detailed evaluation of recent and future developments in this field and of leading companies advances agents that target inflammatory components of atherosclerosis. In particular preclinical and clinical data for Atherogenics' AGI-1067; GSK's Lp-PLA2 inhibitor; DeCode's DG031; Vertex's VX702; Vasogen's Celacade; and Incyte's INC3284 are all critically discussed.